Dr. Elizabeth O'Day has over a decade of experience in metabolomics, biochemistry, and precision medicine. She is the CEO and Founder of Olaris, Inc., a precision medicine company that leverages the myOLARIS toolbox combining metabolomics, machine learning and biology to uncover clinical impactful biomarkers that fundamentally change how diseases are treated and diagnosed.

 

Dr. O’Day serves on the Steering Committee for Scientific American Top 10 Emerging Technologies Council, the World Economic Forum’s Global Biotechnology Council, where she was the co-Chair and the Precision Medicine Initiative. She is also on the Board for the Biological Magnetic Resonance Board and the Precision Medicine Coalition. Dr. O’Day was recognized as a “change maker” by the White House in 2016 at the United State of Women Summit, a “Next Generation Leader” in biotechnology by the Massachusetts Life Science Center in 2018, one of 19 Women to Watch by Women & Wealth Magazine in 2019, a Hubweek Change Maker in 2019, as a 40 under 40 awardee in 2020 by Boston Business Journal and again in 2023 by Worcester Business Journal, and she was also as a Finalist in New England for EY’s Entrepreneur of the Year in 2021 and 2022.

 
Dr. O’Day also supports the next generation of scientists as adjunct faculty at Boston College, where she taught metabolism and entrepreneurship. She is also an active angel investor in emerging biotechnology companies through O’Day Capital, LLC and serves as a Scout for Pillar VC.

 
During her graduate and undergraduate studies, Dr. O’Day received many of the most prestigious research awards. She earned her Ph.D. from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.